Articles about Solutions
Saturday, April 4, 2026
Growth Strategy for Biotech & Pharma Companies
Biotech companies raise capital on clinical promise but grow on commercial execution. The ones that scale build growth infrastructure alongside their pipeline — not after approval forces them to scramble.
Saturday, April 4, 2026
The Founder-Led Marketing Trap
Founder-led marketing is the most authentic, conversion-driving marketing a company can have. It's also the least scalable. When the founder is the brand, the content engine, and the sales closer, growth has a ceiling equal to the founder's time.
Friday, April 3, 2026
Go-to-Market Strategy for Biotech & Pharma Companies
Half of FDA-approved drugs underperform commercial projections in their first year. The difference between the winners and the rest isn't better science — it's better go-to-market strategy built years before launch day.
Friday, April 3, 2026
The End of Growth at All Costs
For a decade, the playbook was simple: raise capital, burn it on acquisition, show growth, raise more. That game is over. The companies winning now are the ones that grow efficiently — where every marketing dollar produces predictable, measurable return.
Friday, April 3, 2026
Fractional CXO for Biotech & Pharma Companies
Biotech companies hire full-time CMOs too early or too late. Too early burns runway on a role the company isn't ready to support. Too late means scrambling to build commercial infrastructure months before launch. A fractional CXO gives you senior leadership on a timeline that matches your pipeline.
Friday, April 3, 2026
The Death of Traditional Marketing Agencies
Traditional marketing agencies charge retainers for junior talent, sell strategy they don't execute, and create dependency they call partnership. The model worked when marketing was simple. It doesn't work when growth requires operators, not vendors.
